HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity

Human Molecular Genetics

Volumn 24, Issue 11, 2014, Pages 3257-3271

  Mattis, Virginia B ^a   Tom, Colton ^a   Akimov, Sergey ^b   Saeedian, Jasmine ^a   Østergaard, Michael E ^c   Southwell, Amber L ^d   Doty, Crystal N ^d   Ornelas, Loren ^a   Sahabian, Anais ^a   Lenaeus, Lindsay ^a   Mandefro, Berhan ^a   Sareen, Dhruv ^a   Arjomand, Jamshid ^e   Hayden, Michael R ^d   Ross, Christopher A ^b   Svendsen, Clive N ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ISIS PHARMACEUTICALS   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLUTAMIC ACID; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NESTIN; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ARTICLE; CAG REPEAT; CELL COUNT; CELL DEATH; CONTROLLED STUDY; GLIA; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; APOPTOSIS; CELL CULTURE; CELL SURVIVAL; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOUSE; ONSET AGE; PATHOLOGY; PHYSIOLOGY;

AGE OF ONSET; ANIMALS; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL SURVIVAL; CELLS, CULTURED; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; INDUCED PLURIPOTENT STEM CELLS; MICE; NEURAL STEM CELLS;

EID: 84930700142     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv080     Document Type: Article

References (98)

1. Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T. and Jette, N. (2012) The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov. Disord., 27, 1083-1091.
2. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
3. Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M. et al. (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet., 4, 387-392.
4. Andrew, S.E., Goldberg, Y.P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., Kalchman, M.A. et al. (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet., 4, 398-403.
5. Estrada Sanchez, A.M., Mejia-Toiber, J. and Massieu, L. (2008) Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch. Med. Res., 39, 265-276.
6. Bergami, M., Rimondini, R., Santi, S., Blum, R., Gotz, M. and Canossa, M. (2008) Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc. Natl Acad. Sci. USA, 105, 15570-15575.
7. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493-498.
8. Zuccato, C. and Cattaneo, E. (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol., 5, 311-322.
9. Canals, J.M., Pineda, J.R., Torres-Peraza, J.F., Bosch, M., Martin-Ibanez, R., Munoz, M.T., Mengod, G., Ernfors, P. and Alberch, J. (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci., 24, 7727-7739.
10. Guidetti, P., Luthi-Carter, R.E., Augood, S.J. and Schwarcz, R. (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis., 17, 455-461.
11. Schwarcz, R. and Coyle, J.T. (1977) Neurochemical sequelae of kainate injections in corpus striatum and substantia nigra of the rat. Life Sci., 20, 431-436.
12. McGeer, E.G. and McGeer, P.L. (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature, 263, 517-519.
13. Martire, A., Pepponi, R., Domenici, M.R., Ferrante, A., Chiodi, V. and Popoli, P. (2013) BDNF prevents NMDAinduced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A(2A) receptor is involved. J. Neurochem, 125, 225-235.
14. Xie, Y., Hayden, M.R. and Xu, B. (2010) BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci., 30, 14708-14718.
15. Suzuki, M., Nelson, A.D., Eickstaedt, J.B., Wallace, K., Wright, L.S. and Svendsen, C.N. (2006) Glutamate enhances proliferation and neurogenesis in human neural progenitor cell cultures derived from the fetal cortex. Eur. J. Neurosci., 24, 645-653.
16. Schlett, K. (2006) Glutamate as a modulator of embryonic and adult neurogenesis. Curr. Top. Med. Chem., 6, 949-960.
17. Sadikot, A.F., Burhan, A.M., Belanger, M.C. and Sasseville, R. (1998) NMDA receptor antagonists influence early development of GABAergic interneurons in the mammalian striatum. Brain Res. Dev. Brain Res., 105, 35-42.
18. Luk, K.C., Kennedy, T.E. and Sadikot, A.F. (2003) Glutamate promotes proliferation of striatal neuronal progenitors by an NMDA receptor-mediated mechanism. J. Neurosci., 23, 2239-2250.
19. Gandhi, R., Luk, K.C., Rymar, V.V. and Sadikot, A.F. (2008) Group I mGluR5 metabotropic glutamate receptors regulate proliferation of neuronal progenitors in specific forebrain developmental domains. J. Neurochem., 104, 155-172.
20. Wagner, W., Bork, S., Horn, P., Krunic, D., Walenda, T., Diehlmann, A., Benes, V., Blake, J., Huber, F.X., Eckstein, V. et al. (2009) Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One, 4, e5846.
21. Pregno, G., Zamburlin, P., Gambarotta, G., Farcito, S., Licheri, V., Fregnan, F., Perroteau, I., Lovisolo, D. and Bovolin, P. (2011) Neuregulin1/ErbB4-induced migration in ST14A striatal progenitors: calcium-dependent mechanisms and modulation by NMDA receptor activation. BMC Neurosci., 12, 103.
22. Ribeiro, F.M., Pires, R.G. and Ferguson, S.S. (2011) Huntington's disease and Group I metabotropic glutamate receptors. Mol. Neurobiol., 43, 1-11.
23. 2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis., 31, 80-88.
24. Zeron, M.M., Hansson, O., Chen, N., Wellington, C.L., Leavitt, B.R., Brundin, P., Hayden, M.R. and Raymond, L.A. (2002) Increased sensitivity to N-methyl-D-aspartate receptormediated excitotoxicity in a mouse model of Huntington's disease. Neuron, 33, 849-860.
25. Arzberger, T., Krampfl, K., Leimgruber, S. and Weindl, A. (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J. Neuropathol. Exp. Neurol., 56, 440-454.
26. Palmada, M. and Centelles, J.J. (1998) Excitatory amino acid neurotransmission. Pathways for metabolism, storage and reuptake of glutamate in brain. Front. Biosci., 3, d701-d718.
27. Bard, J., Wall, M.D., Lazari, O., Arjomand, J. and Munoz-Sanjuan, I. (2014) Advances in huntington disease drug discovery:novel approaches to model disease phenotypes. J. Biomol. Screen, 19, 191-204.
28. Yang, X.W. and Gray, M. (2011) Neurobiology of Huntington's Disease. Mouse Models for Validating Preclinical Candidates for Huntington's Disease. CRC Press, Boca Raton, FL.
29. Seo, H., Sonntag, K.C. and Isacson, O. (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol., 56, 319-328.
30. Varani, K., Abbracchio, M.P., Cannella, M., Cislaghi, G., Giallonardo, P., Mariotti, C., Cattabriga, E., Cattabeni, F., Borea, P.A., Squitieri, F. et al. (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J., 17, 2148-2150.
31. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. and Housman, D. (1999) Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl Acad. Sci. USA, 96, 11404-11409.
32. Yang, X.W., Model, P. and Heintz, N. (1997) Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome. Nat. Biotechnol., 15, 859-865.
33. Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95, 55-66.
34. Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., Olson, J.M. and Cattaneo, E. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet., 11, 1953-1965.
35. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp, A.H., Persichetti, F., Cattaneo, E. and Mac-Donald, M.E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet., 9, 2799-2809.
36. Takahashi, K. and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663-676.
37. Magnuson, T., Epstein, C.J., Silver, L.M. and Martin, G.R. (1982) Pluripotent embryonic stem cell lines can be derived from tw5/tw5 blastocysts. Nature, 298, 750-753.
38. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872.
39. Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R. et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917-1920.
40. Mattis, V.B. and Svendsen, C.N. (2011) Induced pluripotent stem cells: a new revolution for clinical neurology?. Lancet Neurol., 10, 383-394.
41. The HD iPSC Consortium. (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat- expansion-associated phenotypes. Cell Stem Cell, 11, 264-278.
42. Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I.I. and Thomson, J.A. (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324, 797-801.
43. Müller, F.-J., Brändl, B. and Loring, J.F. (2012) Assessment of human pluripotent stem cells with PluriTest. StemBook, edn. The Stem Cell Research Community, StemBook.
44. Molero, A.E., Gokhan, S., Gonzalez, S., Feig, J.L., Alexandre, L. C. and Mehler, M.F. (2009) Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc. Natl Acad. Sci. USA, 106, 21900-21905.
45. Selkoe, D.J., Salazar, F.J., Abraham, C. and Kosik, K.S. (1982) Huntington's disease: changes in striatal proteins reflect astrocytic gliosis. Brain Res., 245, 117-125.
46. Orvoen, S., Pla, P., Gardier, A.M., Saudou, F. and David, D.J. (2012) Huntington's disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation. Neurosci. Lett., 507, 127-132.
47. Simpson, J.M., Gil-Mohapel, J., Pouladi, M.A., Ghilan, M., Xie, Y., Hayden, M.R. and Christie, B.R. (2011) Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol. Dis., 41, 249-260.
48. Grote, H.E., Bull, N.D., Howard, M.L., van Dellen, A., Blakemore, C., Bartlett, P.F. and Hannan, A.J. (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci., 22, 2081-2088.
49. Phillips,W., Morton, A.J. and Barker, R.A. (2005) Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J. Neurosci., 25, 11564-11576.
50. Gray, M., Shirasaki, D.I., Cepeda, C., Andre, V.M., Wilburn, B., Lu, X.H., Tao, J., Yamazaki, I., Li, S.H., Sun, Y.E. et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182-6195.
51. An, M.C., Zhang, N., Scott, G., Montoro, D.,Wittkop, T., Mooney, S., Melov, S. and Ellerby, L.M. (2012) Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell, 11, 253-263.
52. Zhang, N., An, M.C., Montoro, D. and Ellerby, L.M. (2010) Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr., 2, RRN1193.
53. Kornhuber, J., Mack-Burkhardt, F., Kornhuber, M.E. and Riederer, P. (1989) [3H]MK-801 binding sites in post-mortem human frontal cortex. Eur. J. Pharmacol., 162, 483-490.
54. Okamoto, S., Pouladi, M.A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D.E., Zaidi, R., Clemente, A., Kaul, M., Graham, R.K. et al. (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med., 15, 1407-1413.
55. Fan, J., Gladding, C.M., Wang, L., Zhang, L.Y., Kaufman, A.M., Milnerwood, A.J. and Raymond, L.A. (2012) P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis., 45, 999-1009.
56. Rakic, P. (1985) DNA synthesis and cell division in the adult primate brain. Ann. N. Y. Acad. Sci., 457, 193-211.
57. Kaya, S.S., Asim, M., Li, Y., Yavuz, E. and Chopp, M. (1999) Expression of nestin after traumatic brain injury in rat brain. Brain Res., 840, 153-157.
58. Mizuno, Y., Ohama, E., Hirato, J., Nakazato, Y., Takahashi, H., Takatama, M., Takeuchi, T. and Okamoto, K. (2006) Nestin immunoreactivity of Purkinje cells in Creutzfeldt-Jakob disease. J. Neurol. Sci., 246, 131-137.
59. Kandasamy, M., Couillard-Despres, S., Raber, K.A., Stephan, M., Lehner, B., Winner, B., Kohl, Z., Rivera, F.J., Nguyen, H.P., Riess, O. et al. (2010) Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-beta signaling in an animal model of Huntington disease. J. Neuropathol. Exp. Neurol., 69, 717-728.
60. Bath, K.G., Mandairon, N., Jing, D., Rajagopal, R., Kapoor, R., Chen, Z.Y., Khan, T., Proenca, C.C., Kraemer, R., Cleland, T.A. et al. (2008) Variant brain-derived neurotrophic factor (Val66-Met) alters adult olfactory bulb neurogenesis and spontaneous olfactory discrimination. J. Neurosci., 28, 2383-2393.
61. Sairanen, M., Lucas, G., Ernfors, P., Castren, M. and Castren, E. (2005) Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci., 25, 1089-1094.
62. Scharfman, H., Goodman, J., Macleod, A., Phani, S., Antonelli, C. and Croll, S. (2005) Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp. Neurol., 192, 348-356.
63. Henry, R.A., Hughes, S.M. and Connor, B. (2007) AAVmediated delivery of BDNF augments neurogenesis in the normal and quinolinic acid-lesioned adult rat brain. Eur. J. Neurosci., 25, 3513-3525.
64. Bath, K.G., Akins, M.R. and Lee, F.S. (2012) BDNF control of adult SVZ neurogenesis. Dev. Psychobiol., 54, 578-589.
65. Curtis, M.A., Penney, E.B., Pearson, A.G., van Roon-Mom, W. M., Butterworth, N.J., Dragunow, M., Connor, B. and Faull, R. L. (2003) Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl Acad. Sci. USA, 100, 9023-9027.
66. Gil, J.M., Mohapel, P., Araújo, I.M., Popovic, N., Li, J.Y., Brundin, P. and Petersén, A. (2005) Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. Neurobiol. Dis., 20, 744-751.
67. Cho, S.R., Benraiss, A., Chmielnicki, E., Samdani, A., Economides, A. and Goldman, S.A. (2007) Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J. Clin. Invest., 117, 2889-2902.
68. Sun, Y., Savanenin, A., Reddy, P.H. and Liu, Y.F. (2001) Polyglutamine- expanded huntingtin promotes sensitization of Nmethyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem., 276, 24713-24718.
69. Ali, D.W. and Salter, M.W. (2001) NMDAreceptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity. Curr. Opin. Neurobiol., 11, 336-342.
70. LoTurco, J.J., Owens, D.F., Heath, M.J., Davis, M.B. and Kriegstein, A.R. (1995) GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis. Neuron, 15, 1287-1298.
71. Anborgh, P.H., Godin, C., Pampillo, M., Dhami, G.K., Dale, L.B., Cregan, S.P., Truant, R. and Ferguson, S.S. (2005) Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J. Biol. Chem., 280, 34840-34848.
72. DiFiglia, M. (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci., 13, 286-289.
73. Nicoletti, F., Bruno, V., Copani, A., Casabona, G. and Knöpfel, T. (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?. Trends Neurosci., 19, 267-271.
74. Bruno, V., Battaglia, G., Copani, A., D'Onofrio, M., Di Iorio, P., De Blasi, A., Melchiorri, D., Flor, P.J. and Nicoletti, F. (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow. Metab., 21, 1013-1033.
75. Tang, T.S., Tu, H., Chan, E.Y., Maximov, A.,Wang, Z.,Wellington, C.L., Hayden, M.R. and Bezprozvanny, I. (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron, 39, 227-239.
76. Schiefer, J., Sprünken, A., Puls, C., Lüesse, H.G., Milkereit, A., Milkereit, E., Johann, V. and Kosinski, C.M. (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res., 1019, 246-254.
77. Baskys, A., Fang, L. and Bayazitov, I. (2005) Activation of neuroprotective pathways by metabotropic group I glutamate receptors: a potential target for drug discovery?. Ann. N. Y. Acad. Sci., 1053, 55-73.
78. Baskys, A., Bayazitov, I., Fang, L., Blaabjerg, M., Poulsen, F.R. and Zimmer, J. (2005) Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis. Neuropharmacology, 49 Suppl 1, 146-156.
79. Baskys, A. and Blaabjerg, M. (2005) Understanding regulation of nerve cell death by mGluRs as a method for development of successful neuroprotective strategies. J. Neurol. Sci., 229-230, 201-209.
80. Zeron, M.M., Fernandes, H.B., Krebs, C., Shehadeh, J.,Wellington, C.L., Leavitt, B.R., Baimbridge, K.G., Hayden, M.R. and Raymond, L.A. (2004) Potentiation of NMDA receptormediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell Neurosci., 25, 469-479.
81. Chen, N., Luo, T.,Wellington, C., Metzler, M., McCutcheon, K., Hayden, M.R. and Raymond, L.A. (1999) Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem., 72, 1890-1898.
82. Ernst,A.,Alkass,K., Bernard, S.,Salehpour,M., Perl, S.,Tisdale, J., Possnert, G., Druid, H. and Frisen, J. (2014) Neurogenesis in the striatum of the adult human brain. Cell, 156, 1072-1083.
83. Ferrer, I., Goutan, E., Marin, C., Rey, M.J. and Ribalta, T. (2000) Brain-derived neurotrophic factor in Huntington disease. Brain Res., 866, 257-261.
84. Giampa, C., Montagna, E., Dato, C., Melone, M.A., Bernardi, G. and Fusco, F.R. (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS One, 8, e64037.
85. Jiang, M., Peng, Q., Liu, X., Jin, J., Hou, Z., Zhang, J., Mori, S., Ross, C.A., Ye, K. and Duan,W. (2013) Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum. Mol. Genet, 12, 2462-2470.
86. Simmons, D.A., Belichenko, N.P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S.M. and Longo, F.M. (2013) A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J. Neurosci., 48, 18712-18727. Erratum in: J Neurosci. (2014) 5.
87. Luong, M.X., Auerbach, J., Crook, J.M., Daheron, L., Hei, D., Lomax, G., Loring, J.F., Ludwig, T., Schlaeger, T.M., Smith, K.P. et al. (2011) A call for standardized naming and reporting of human ESC and iPSC lines. Cell Stem Cell, 8, 357-359.
88. Sareen, D., Ebert, A.D., Heins, B.M., McGivern, J.V., Ornelas, L. and Svendsen, C.N. (2012) Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One, 7, e39113.
89. Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K. et al. (2011) A more efficient method to generate integrationfree human iPS cells. Nat. Methods, 8, 409-412.
90. Muller, F.J., Schuldt, B.M., Williams, R., Mason, D., Altun, G., Papapetrou, E.P., Danner, S., Goldmann, J.E., Herbst, A., Schmidt, N.O. et al. (2011) A bioinformatic assay for pluripotency in human cells. Nat. Methods, 8, 315-317.
91. Ebert, A.D., Shelley, B.C., Hurley, A.M., Onorati, M., Castiglioni, V., Patitucci, T.N., Svendsen, S.P., Mattis, V.B., McGivern, J.V., Schwab, A.J. et al. (2013) EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs. Stem Cell Res., 10, 417-427.
92. Pruunsild, P., Sepp, M., Orav, E., Koppel, I. and Timmusk, T. (2011) Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J. Neurosci., 31, 3295-3308.
93. Skotte, N.H., Southwell, A.L., Ostergaard, M.E., Carroll, J.B., Warby, S.C., Doty, C.N., Petoukhov, E., Vaid, K., Kordasiewicz, H., Watt, A.T. et al. (2014) Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all huntington disease patients. PLoS One, 9, e107434.
94. Ostergaard, M.E., Southwell, A.L., Kordasiewicz, H.,Watt, A.T., Skotte, N.H., Doty, C.N., Vaid, K., Villanueva, E.B., Swayze, E.E., Bennett, C.F. et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res., 41, 9634-9650.
95. Southwell, A.L., Skotte, N.H., Kordasiewicz, H.B., Ostergaard, M.E., Watt, A.T., Carroll, J.B., Doty, C.N., Villanueva, E.B., Petoukhov, E., Vaid, K. et al. (2014) In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol. Ther, 12, 2093-2106.
96. Carroll, J.B.,Warby, S.C., Southwell, A.L., Doty, C.N., Greenlee, S., Skotte, N., Hung, G., Bennett, C.F., Freier, S.M. and Hayden, M.R. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther., 19, 2178-2185.
97. Aubry, L., Bugi, A., Lefort, N., Rousseau, F., Peschanski, M. and Perrier, A.L. (2008) Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc. Natl Acad. Sci. USA, 105, 16707-16712.
98. Ebert, A.D., McMillan, E.L. and Svendsen, C.N. (2008) Isolating, expanding, and infecting human and rodent fetal neural progenitor cells. Curr. Protoc. Stem Cell Biol., Chapter 2, Unit 2D 2.